Cargando…

Apoptosis: Targets in Pancreatic Cancer

Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue h...

Descripción completa

Detalles Bibliográficos
Autores principales: Westphal, Sabine, Kalthoff, Holger
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149420/
https://www.ncbi.nlm.nih.gov/pubmed/12605713
http://dx.doi.org/10.1186/1476-4598-2-6
_version_ 1782120634435764224
author Westphal, Sabine
Kalthoff, Holger
author_facet Westphal, Sabine
Kalthoff, Holger
author_sort Westphal, Sabine
collection PubMed
description Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease.
format Text
id pubmed-149420
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1494202003-02-25 Apoptosis: Targets in Pancreatic Cancer Westphal, Sabine Kalthoff, Holger Mol Cancer Review Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease. BioMed Central 2003-01-07 /pmc/articles/PMC149420/ /pubmed/12605713 http://dx.doi.org/10.1186/1476-4598-2-6 Text en Copyright © 2003 Westphal and Kalthoff; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Review
Westphal, Sabine
Kalthoff, Holger
Apoptosis: Targets in Pancreatic Cancer
title Apoptosis: Targets in Pancreatic Cancer
title_full Apoptosis: Targets in Pancreatic Cancer
title_fullStr Apoptosis: Targets in Pancreatic Cancer
title_full_unstemmed Apoptosis: Targets in Pancreatic Cancer
title_short Apoptosis: Targets in Pancreatic Cancer
title_sort apoptosis: targets in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149420/
https://www.ncbi.nlm.nih.gov/pubmed/12605713
http://dx.doi.org/10.1186/1476-4598-2-6
work_keys_str_mv AT westphalsabine apoptosistargetsinpancreaticcancer
AT kalthoffholger apoptosistargetsinpancreaticcancer